ClinicalTrials.gg
CompletedNCT01058707Updated Apr 1, 2020Results posted

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

A Phase 1 interventional study of MLN0128 in Advanced Solid Malignancies, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-01.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
198
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase I, open label, Dose Escalation study of oral administration of single agent MLN0128 in participants with Advanced Malignancies followed by an Expansion Phase in participants with renal cell carcinoma, endometrial cancer or urothelial cancer who have measurable disease.

Read the detailed description

The drug being tested in this study is called MLN0128. MLN0128 is being tested to treat people who have Advanced Malignancies.

The study enrolled approximately 198 patients. Participants were assigned to one of the following dose regimens in the Dose Escalation Phase to establish the Maximum Tolerated Dose (MTD):

  • MLN0128 QD
  • MLN0128 QW
  • MLN0128 QDx3dQW
  • MLN0128 QDx5dQW

MLN0128 capsule, orally, once daily (QD) or Once weekly (QW) in the Dose Escalation Phase until MTD was established.

Once MTD was determined, participants were then enrolled in the Dose Expansion Phase to receive:

  • MLN0128 5 mg QD
  • MLN0128 30 mg QW
  • MLN0128 40 mg QW

This multi-centre trial was conducted worldwide. The overall time to participate in this study was approximately 244 weeks. Participants will make multiple visits to the clinic, and were contacted by telephone OR plus a final visit after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Advanced Solid Malignancies

Keywords

  • Solid tumors, MLN0128, TORC1/2 inhibitors
03

In context

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written consent
  • Locally advanced or solid tumors with the exception of primary brain tumor, and have failed standard of care therapy
  • (ECOG) performance status 0-1
  • Ability to swallow oral medications
  • For women of , negative serum or urine pregnancy test within 14 days prior to the first study drug administration and use of physician-approved method of from 30 days prior to 90 days following the last study drug administration
  • Male participants must be surgically sterile or must agree to use physician-approved contraception during the study and for 90 days following the last study drug administration
  • Clinical laboratory values as specified in the protocol

Additionally, to be eligible for the Dose Expansion portion of the study:

  • Participants must have evidence of per (RECIST) version 1.1 by radiographic techniques or magnetic resonance imaging
  • Participants must have a pathologic diagnosis of advanced or recurrent endometrial adenocarcinoma and must have failed at least 1 prior line of standard chemotherapy
  • Participants must have a pathologic diagnosis of advanced/metastatic urothelial cancer (carcinoma of the bladder, ureter, and/or renal pelvis) and must have failed at least 1 in the metastatic/unresectable setting
  • Participants must have a pathologic diagnosis of advanced renal cell carcinoma (RCC), with histological or cytological confirmation of RCC and must have failed at least 1 prior line of anti-vascular endothelial growth factor therapy (VEGF) therapy (including but not limited to sunitinib, and/or sorafenib, and/or bevacizumab and/or pazopanib, and/or axitinib) and must not have received prior therapy with a target of rapamycin complex 1 (TORC1) inhibitor (such as temsirolimus or everolimus); or
  • Participants must have a pathologic diagnosis of advanced renal cell carcinoma (RCC) and must have progressed on treatment with a TORC1 inhibitor (such as temsirolimus or everolimus).

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of primary brain tumor
  • Have received prior cancer or other therapy within 2 weeks prior to the first administration of study drug
  • Known impaired cardiac function or cardiac disease
  • Known treatment with systemic within one week prior to the first administration of study drug
  • Diabetes mellitus
  • (HIV) infection
  • Known active cardiovascular disease condition as specified in protocol
  • Failed to recover from the reversible effects of prior anticancer therapies
  • Pregnancy (positive serum or urine pregnancy test) or breast feeding
  • Malabsorption due to prior gastrointestinal (GI) surgery, GI disease
  • Other clinically significant co-morbidities

Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.

Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    MLN0128 QD

    MLN0128 2 mg, 4 mg, 6 mg or 7 mg, capsule, orally, once daily (QD) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 52.1 weeks).

    Drug: MLN0128

  • Experimental
    MLN0128 QW

    MLN0128 7 mg, 10 mg, 15 mg, 20 mg, 30 mg or 40 mg capsule, orally, once weekly (QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 139.4 weeks).

    Drug: MLN0128

  • Experimental
    MLN0128 QDx3d QW

    MLN0128 6 mg, 9 mg, 12 mg, 16 mg or 20 mg capsule, orally, once daily every 3 days a week (QDx3d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 129.4 weeks).

    Drug: MLN0128

  • Experimental
    MLN0128 QDx5d QW

    MLN0128 7 mg, 10 mg or 13 mg capsule, orally, once daily every 5 days a week (QDx5d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 161.9 weeks).

    Drug: MLN0128

  • Experimental
    MLN0128 5 mg QD

    MLN0128 5 mg, capsule, orally, QD in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 98.3 weeks).

    Drug: MLN0128

  • Experimental
    MLN0128 30 mg QW

    MLN0128 30 mg, capsule, orally QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 240 weeks).

    Drug: MLN0128

  • Experimental
    MLN0128 40 mg QW

    MLN0128 40 mg, capsule, orally, QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 100.1 weeks).

    Drug: MLN0128

Interventions

  • MLN0128 capsules

    Also known as: INK128, TAK-128

06

What researchers measure

Primary outcomes

  1. Dose Escalation Phase: Maximum Tolerated Dose (MTD)

    MTD was defined as the highest dose level of MLN0128 at which no more than 1 out of 6 evaluable participants experienced a DLT during the first cycle (28 days) of therapy.

    Time frame: Cycle 1 (28 Days)

  2. Dose Escalation Phase: Number of Participants With Dose Limiting Toxicities (DLTs)

    DLTs were defined as MLN0128-related treatment-emergent adverse events (TEAEs) that occurred within the Cycle 1 (first 28 days of treatment) as per Common Terminology Criteria for Adverse Events (CTCAE): Any ≥Grade 3 or non-hematologic toxicity except for Grade 3 nausea and/or vomiting and diarrhea, Grade 3 hyperglycemia lasting ≤ 14 days, Grade 3 rash lasting ≤ 3 days; Grade 4 neutropenia lasting \>7 days in the absence of growth factor support; Grade 4 neutropenia of any duration associated with fever ≥38.5 degree celsius and/or systemic infection; Any other Grade 4 hematologic toxicity; Inability to administer at least 75% of planned doses of MLN0128 within Cycle 1 due to drug-related toxicity and any clinically significant occurrence that the investigators and sponsor agreed would place participants at an undue safety risk.

    Time frame: Cycle 1 (28 days)

  3. Number of Participants Experiencing One or More Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Resulting in Discontinuation of MLN0128 and Fatal AEs Within 30 Days of Last Dose of Study Drug

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: First dose of study drug through 30 days after the administration of the last dose of study drug (Up to approximately 244 weeks)

  4. Dose Expansion: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who achieved complete response (CR) or partial response (PR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. CR is defined as disappearance of all target lesions and PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions. Data was categorized as per type of cancer.

    Time frame: From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)

  5. Dose Expansion Phase: Duration of Objective Response

    Duration of objective response is defined as the number of months from the start date of CR or PR (whichever occurred first) based on RECIST Criteria version 1.1 to the first date of objectively documented progressive disease (PD) for participants who achieved CR or PR. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

    Time frame: From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)

  6. Dose Expansion: Duration of Stable Disease (SD)

    Duration of SD was evaluated for participants with best response of SD and is defined as number of months from date of first dose to date of PD. As per RECIST 1.1, SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PR was defined of at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions. PD is defined as at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (this includes baseline sum if that is smallest on study).

    Time frame: From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)

Secondary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for MLN0128

    Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2

  2. Ctrough: Observed Concentration at the End of a Dosing Interval

    Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2

  3. Terminal Phase Elimination Half-life (T1/2) for MLN0128

    Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2

  4. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN0128

    Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2

  5. AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MLN0128

    Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2

  6. Tmax: Time to Maximum Observed Plasma Concentration for MLN0128

    Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2

  7. Percentage Area Under Plasma Concentration Time Curve Extrapolated

    Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2

  8. Percentage Change From Baseline in Eukaryotic Initiation Factor 4E-binding Protein 1 (P4EBP1), Serine/Threonine Protein Kinase B (PAKT) and Ribosomal Protein S6 (PS6)

    P4EBP, PAKT and PS6 were assayed in skin biopsies. A negative percentage change from Baseline indicates improvement.

    Time frame: Baseline, Cycle 1 Week 2

07

Results

Posted Apr 1, 2020

Participant flow

Participants took part in the study at 15 investigative sites in Spain and the United States from 4 January 2010 to 7 February 2019.

Participant flow — Overall Study
MilestoneMLN0128 QDMLN0128 QWMLN0128 QDx3d QWMLN0128 QDx5d QWMLN0128 5 mg QDMLN0128 30 mg QWMLN0128 40 mg QW
Started31303322391726
Completed0000000
Not completed31303322391726
Withdrew: Disease progression15202015231012
Withdrew: Adverse event11476731
Withdrew: Subject decision5331236
Withdrew: Lost to follow-up0010000
Withdrew: Reason not specified0320717

Outcome measures

PrimaryDose Escalation Phase: Maximum Tolerated Dose (MTD)

MTD was defined as the highest dose level of MLN0128 at which no more than 1 out of 6 evaluable participants experienced a DLT during the first cycle (28 days) of therapy.

Time frame:
Cycle 1 (28 Days)
Reported as:
Number · milligrams (mg)
Dose Escalation Phase: Maximum Tolerated Dose (MTD)
milligrams (mg)MLN0128 QDMLN0128 QWMLN0128 QDx3d QWMLN0128 QDx5d QW
Dose Escalation Phase: Maximum Tolerated Dose (MTD)64097
PrimaryDose Escalation Phase: Number of Participants With Dose Limiting Toxicities (DLTs)

DLTs were defined as MLN0128-related treatment-emergent adverse events (TEAEs) that occurred within the Cycle 1 (first 28 days of treatment) as per Common Terminology Criteria for Adverse Events (CTCAE): Any ≥Grade 3 or non-hematologic toxicity except for Grade 3 nausea and/or vomiting and diarrhea, Grade 3 hyperglycemia lasting ≤ 14 days, Grade 3 rash lasting ≤ 3 days; Grade 4 neutropenia lasting \>7 days in the absence of growth factor support; Grade 4 neutropenia of any duration associated with fever ≥38.5 degree celsius and/or systemic infection; Any other Grade 4 hematologic toxicity; Inability to administer at least 75% of planned doses of MLN0128 within Cycle 1 due to drug-related toxicity and any clinically significant occurrence that the investigators and sponsor agreed would place participants at an undue safety risk.

Time frame:
Cycle 1 (28 days)
Reported as:
Count of participants · Participants
Dose Escalation Phase: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsMLN0128 QDMLN0128 QWMLN0128 QDx3d QWMLN0128 QDx5d QW
Dose Escalation Phase: Number of Participants With Dose Limiting Toxicities (DLTs)7267
PrimaryNumber of Participants Experiencing One or More Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Resulting in Discontinuation of MLN0128 and Fatal AEs Within 30 Days of Last Dose of Study Drug

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
First dose of study drug through 30 days after the administration of the last dose of study drug (Up to approximately 244 weeks)
Reported as:
Count of participants · Participants
Number of Participants Experiencing One or More Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Resulting in Discontinuation of MLN0128 and Fatal AEs Within 30 Days of Last Dose of Study Drug
ParticipantsMLN0128 QDMLN0128 QWMLN0128 QDx3d QWMLN0128 QDx5d QWMLN0128 5 mg QDMLN0128 30 mg QWMLN0128 40 mg QW
TEAE31303322391726
SAE131017101969
AEs Resulting in Discontinuation of MLN012811476732
Fatal AEs within 30 Days of Last Dose Study Drug1120021
PrimaryDose Expansion: Objective Response Rate (ORR)

ORR is defined as the percentage of participants who achieved complete response (CR) or partial response (PR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. CR is defined as disappearance of all target lesions and PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions. Data was categorized as per type of cancer.

Time frame:
From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
Reported as:
Number · percentage of participants
Dose Expansion: Objective Response Rate (ORR)
percentage of participantsMLN0128 5 mg QDMLN0128 30 mg QWMLN0128 40 mg QW
Cancer Type: Renal151315
Cancer Type: Endometrial900
Cancer Type: Bladder000
PrimaryDose Expansion Phase: Duration of Objective Response

Duration of objective response is defined as the number of months from the start date of CR or PR (whichever occurred first) based on RECIST Criteria version 1.1 to the first date of objectively documented progressive disease (PD) for participants who achieved CR or PR. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

Time frame:
From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
Reported as:
Median · months
Dose Expansion Phase: Duration of Objective Response
monthsMLN0128 5 mg QDMLN0128 30 mg QWMLN0128 40 mg QW
Dose Expansion Phase: Duration of Objective Response8.90 (3.48 to 23.06)56.05 (56.05 to 56.05)20.73 (20.24 to 21.22)
PrimaryDose Expansion: Duration of Stable Disease (SD)

Duration of SD was evaluated for participants with best response of SD and is defined as number of months from date of first dose to date of PD. As per RECIST 1.1, SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PR was defined of at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions. PD is defined as at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (this includes baseline sum if that is smallest on study).

Time frame:
From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
Reported as:
Median · months
Dose Expansion: Duration of Stable Disease (SD)
monthsMLN0128 5 mg QDMLN0128 30 mg QWMLN0128 40 mg QW
Dose Expansion: Duration of Stable Disease (SD)3.68 (0.95 to 14.88)2.20 (0.76 to 5.45)3.55 (1.18 to 13.08)
SecondaryCmax: Maximum Observed Plasma Concentration for MLN0128
Time frame:
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for MLN0128
ng/mLMLN0128 2 mg QDMLN0128 4 mg QDMLN0128 6 mg QDMLN0128 7 mg QDMLN0128 7 mg QWMLN0128 10 mg QWMLN0128 15 mg QWMLN0128 20 mg QWMLN0128 30 mg QWMLN0128 40 mg QWMLN0128 6 mg QDx3dQWMLN0128 9 mg QDx3d QWMLN0128 12 mg QDx3d QWMLN0128 16 mg QDx3d QWMLN0128 20 mg QDx3dQWMLN0128 7 mg QDx5dQWMLN0128 10 mg QDx5dQWMLN0128 13 mg QDx5dQW
Cycle 1 Day 113.7 (12.30 to 16.30)20.5 (9.54 to 35.70)48.9 (18.60 to 75.60)67.8 (21.10 to 143.00)43.6 (16.20 to 94.40)75.9 (43.60 to 139.00)80.2 (24.30 to 173.00)136.6 (66.80 to 217.00)174.0 (101.00 to 259.00)193.8 (57.90 to 358.00)88.5 (72.90 to 115.00)82.9 (25.00 to 111.00)124.3 (50.90 to 320.00)78.5 (35.20 to 184.00)194.0 (118.00 to 300.00)46.9 (18.80 to 79.00)48.5 (22.60 to 76.50)110.1 (42.30 to 181.00)
Cycle 2 Day 116.2 (12.00 to 22.70)22.1 (11.90 to 35.90)39.4 (24.00 to 76.40)65.0 (28.20 to 130.00)66.7 (55.80 to 77.60)40.5 (22.40 to 58.50)66.9 (47.70 to 87.90)134.00 (134.00 to 134.00)142.6 (96.70 to 222.00)249.8 (140.00 to 394.00)60.0 (52.50 to 74.40)87.7 (46.80 to 118.00)115.1 (93.40 to 143.00)113.6 (42.50 to 292.00)183.00 (183.00 to 183.00)60.1 (23.50 to 126.00)60.0 (32.00 to 95.70)96.50 (96.50 to 96.50)
SecondaryCtrough: Observed Concentration at the End of a Dosing Interval
Time frame:
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Reported as:
Mean · ng/mL
Ctrough: Observed Concentration at the End of a Dosing Interval
ng/mLMLN0128 2 mg QDMLN0128 4 mg QDMLN0128 6 mg QDMLN0128 7 mg QDMLN0128 7 mg QWMLN0128 10 mg QWMLN0128 15 mg QWMLN0128 20 mg QWMLN0128 30 mg QWMLN0128 40 mg QWMLN0128 6 mg QDx3dQWMLN0128 9 mg QDx3d QWMLN0128 12 mg QDx3d QWMLN0128 16 mg QDx3d QWMLN0128 20 mg QDx3dQWMLN0128 7 mg QDx5dQWMLN0128 10 mg QDx5dQWMLN0128 13 mg QDx5dQW
Cycle 1 Day 10.9 (0.00 to 2.76)1.2 (0.00 to 2.48)3.5 (0.00 to 8.84)4.4 (1.15 to 9.22)——————2.5 (0.00 to 5.01)6.8 (0.00 to 16.80)9.9 (1.83 to 22.90)8.1 (0.00 to 21.50)44.7 (6.35 to 123.00)3.1 (2.02 to 4.48)3.6 (0.00 to 10.10)21.7 (5.85 to 43.70)
Cycle 2 Day 14.5 (1.48 to 9.76)3.7 (0.00 to 10.30)4.5 (3.07 to 9.37)3.0 (1.24 to 6.23)——————10.3 (0.00 to 25.10)10.8 (5.03 to 25.50)4.4 (3.34 to 5.38)10.0 (0.00 to 27.10)11.40 (11.40 to 11.40)5.2 (1.82 to 11.20)3.0 (1.08 to 4.68)6.58 (6.58 to 6.58)
SecondaryTerminal Phase Elimination Half-life (T1/2) for MLN0128
Time frame:
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Reported as:
Median · hours
Terminal Phase Elimination Half-life (T1/2) for MLN0128
hoursMLN0128 2 mg QDMLN0128 4 mg QDMLN0128 6 mg QDMLN0128 7 mg QDMLN0128 7 mg QWMLN0128 10 mg QWMLN0128 15 mg QWMLN0128 20 mg QWMLN0128 30 mg QWMLN0128 40 mg QWMLN0128 6 mg QDx3dQWMLN0128 9 mg QDx3d QWMLN0128 12 mg QDx3d QWMLN0128 16 mg QDx3d QWMLN0128 20 mg QDx3dQWMLN0128 7 mg QDx5dQWMLN0128 10 mg QDx5dQWMLN0128 13 mg QDx5dQW
Cycle 1 Day 110.3 (10.30 to 10.30)7.4 (5.27 to 8.22)6.3 (4.86 to 10.40)6.2 (5.66 to 6.23)6.47 (6.47 to 6.47)5.8 (5.72 to 5.95)9.4 (6.99 to 11.90)5.7 (4.11 to 11.60)5.5 (5.30 to 6.94)7.1 (4.07 to 12.70)5.5 (5.15 to 5.93)7.9 (6.53 to 8.12)6.4 (4.71 to 11.10)7.2 (4.59 to 9.52)5.5 (5.10 to 5.84)7.8 (5.26 to 9.38)6.5 (4.72 to 10.10)8.7 (8.20 to 9.16)
Cycle 2 Day 18.1 (7.49 to 8.75)9.7 (9.47 to 11.70)7.9 (5.83 to 8.06)4.9 (3.99 to 7.85)5.6 (4.91 to 6.19)—8.01 (8.01 to 8.01)4.57 (4.57 to 4.57)5.7 (5.08 to 6.35)5.6 (4.29 to 9.02)9.1 (6.05 to 12.10)7.0 (6.01 to 7.85)4.9 (4.63 to 5.11)6.4 (3.61 to 10.30)6.28 (6.28 to 6.28)6.8 (6.18 to 7.14)5.6 (4.19 to 7.58)6.42 (6.42 to 6.42)
SecondaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN0128
Time frame:
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Reported as:
Mean · ng*hr/mL
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN0128
ng*hr/mLMLN0128 2 mg QDMLN0128 4 mg QDMLN0128 6 mg QDMLN0128 7 mg QDMLN0128 7 mg QWMLN0128 10 mg QWMLN0128 15 mg QWMLN0128 20 mg QWMLN0128 30 mg QWMLN0128 40 mg QWMLN0128 6 mg QDx3dQWMLN0128 9 mg QDx3d QWMLN0128 12 mg QDx3d QWMLN0128 16 mg QDx3d QWMLN0128 20 mg QDx3dQWMLN0128 7 mg QDx5dQWMLN0128 10 mg QDx5dQWMLN0128 13 mg QDx5dQW
Cycle 1 Day 1185.00 (185.00 to 185.00)205.3 (145.00 to 269.00)390.6 (263.00 to 608.00)459.5 (195.00 to 585.00)440.00 (440.00 to 440.00)609.0 (241.00 to 977.00)1014.5 (179.00 to 1850.00)1172.7 (563.00 to 2190.00)1316.3 (759.00 to 2290.00)2149.8 (844.00 to 4310.00)494.0 (411.00 to 577.00)725.2 (388.00 to 903.00)922.8 (383.00 to 1470.00)820.1 (389.00 to 1220.00)1245.0 (1080.00 to 1410.00)326.2 (240.00 to 423.00)388.5 (231.00 to 761.00)941.5 (483.00 to 1400.00)
Cycle 2 Day 1————371.0 (354.00 to 388.00)—510.00 (510.00 to 510.00)1030.00 (1030.00 to 1030.00)1427.5 (745.00 to 2110.00)2876.6 (903.00 to 6110.00)————————
SecondaryAUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MLN0128
Time frame:
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Reported as:
Mean · ng*hr/mL
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MLN0128
ng*hr/mLMLN0128 2 mg QDMLN0128 4 mg QDMLN0128 6 mg QDMLN0128 7 mg QDMLN0128 7 mg QWMLN0128 10 mg QWMLN0128 15 mg QWMLN0128 20 mg QWMLN0128 30 mg QWMLN0128 40 mg QWMLN0128 6 mg QDx3dQWMLN0128 9 mg QDx3d QWMLN0128 12 mg QDx3d QWMLN0128 16 mg QDx3d QWMLN0128 20 mg QDx3dQWMLN0128 7 mg QDx5dQWMLN0128 10 mg QDx5dQWMLN0128 13 mg QDx5dQW
Cycle 1 Day 165.4 (64.00 to 66.80)65.3 (51.60 to 89.80)95.30 (95.30 to 95.30)—72.80 (72.80 to 72.80)106.00 (106.00 to 106.00)————162.00 (162.00 to 162.00)207.5 (198.00 to 217.00)—130.2 (93.40 to 167.00)——221.00 (221.00 to 221.00)—
Cycle 2 Day 1—62.2 (56.30 to 68.00)———105.00 (105.00 to 105.00)————182.00 (182.00 to 182.00)——197.00 (197.00 to 197.00)————
SecondaryTmax: Time to Maximum Observed Plasma Concentration for MLN0128
Time frame:
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Reported as:
Median · hours
Tmax: Time to Maximum Observed Plasma Concentration for MLN0128
hoursMLN0128 2 mg QDMLN0128 4 mg QDMLN0128 6 mg QDMLN0128 7 mg QDMLN0128 7 mg QWMLN0128 10 mg QWMLN0128 15 mg QWMLN0128 20 mg QWMLN0128 30mg QWMLN0128 40 mg QWMLN0128 6 mg QDx3dQWMLN0128 9 mg QDx3d QWMLN0128 12 mg QDx3d QWMLN0128 16 mg QDx3d QWMLN0128 20 mg QDx3dQWMLN0128 7 mg QDx5dQWMLN0128 10 mg QDx5dQWMLN0128 13 mg QDx5dQW
Cycle 1 Day 12.0 (2.00 to 2.05)2.0 (0.98 to 4.00)1.0 (0.50 to 4.17)1.5 (0.50 to 7.57)2.1 (0.52 to 8.00)1.0 (1.00 to 1.97)2.0 (1.07 to 2.00)2.0 (1.00 to 2.15)1.0 (1.00 to 4.00)2.4 (1.00 to 4.53)0.6 (0.50 to 1.15)1.1 (0.55 to 4.33)2.0 (0.55 to 4.05)2.1 (0.50 to 8.67)3.1 (0.53 to 4.05)1.2 (0.50 to 4.08)4.0 (0.53 to 4.33)2.1 (1.08 to 8.00)
Cycle 2 Day 12.0 (1.97 to 2.00)3.8 (1.00 to 4.03)2.0 (1.03 to 4.42)4.0 (1.00 to 4.03)1.02 (1.02 to 1.02)2.9 (1.80 to 4.00)2.0 (2.00 to 8.00)4.0 (4.00 to 4.00)4.0 (1.03 to 7.92)2.0 (1.00 to 8.00)4.0 (1.00 to 4.00)2.1 (0.50 to 7.57)3.7 (1.00 to 4.18)2.1 (0.53 to 8.00)1.0 (1.00 to 1.00)1.5 (0.97 to 7.42)2.0 (0.52 to 3.58)2.02 (2.02 to 2.02)
SecondaryPercentage Area Under Plasma Concentration Time Curve Extrapolated
Time frame:
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2

No measurements were reported for this outcome.

SecondaryPercentage Change From Baseline in Eukaryotic Initiation Factor 4E-binding Protein 1 (P4EBP1), Serine/Threonine Protein Kinase B (PAKT) and Ribosomal Protein S6 (PS6)

P4EBP, PAKT and PS6 were assayed in skin biopsies. A negative percentage change from Baseline indicates improvement.

Time frame:
Baseline, Cycle 1 Week 2
Reported as:
Mean · percentage change
Percentage Change From Baseline in Eukaryotic Initiation Factor 4E-binding Protein 1 (P4EBP1), Serine/Threonine Protein Kinase B (PAKT) and Ribosomal Protein S6 (PS6)
percentage changeMLN0128 QDMLN0128 QWMLN0128 QDx3d QWMLN0128 QDx5d QW
p4EBP1-64.1 ± 47.65-15.5 ± 378.88-99.5 ± 2.7587.4 ± 43.83
pAKT27.1 ± 73.7826.9 ± 139.7573.3 ± 115.55168.9 ± 514.88
pS6-50.2 ± 43.89-42.7 ± 59.64-68.2 ± 37.98-82.5 ± 12.15

Adverse events

Collected over All cause-mortality were collected throughout the study; SAEs and Other (non-serious) were collected from the first dose of study drug plus 30 days after last dose of study drug (Up to approximately 244 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MLN0128 QD3/31 (9.7%)13/31 (41.9%)31/31 (100%)
MLN0128 QW2/30 (6.7%)10/30 (33.3%)30/30 (100%)
MLN0128 QDx3d QW2/33 (6.1%)17/33 (51.5%)33/33 (100%)
MLN0128 QDx5d QW0/22 (0%)10/22 (45.5%)22/22 (100%)
MLN0128 5 mg QD2/39 (5.1%)19/39 (48.7%)39/39 (100%)
MLN0128 30 mg QW2/17 (11.8%)6/17 (35.3%)17/17 (100%)
MLN0128 40 mg QW3/26 (11.5%)9/26 (34.6%)26/26 (100%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventMLN0128 QDMLN0128 QWMLN0128 QDx3d QWMLN0128 QDx5d QWMLN0128 5 mg QDMLN0128 30 mg QWMLN0128 40 mg QW
StomatitisGastrointestinal disorders0/310/304/332/220/390/171/26
Pain in extremityMusculoskeletal and connective tissue disorders0/310/300/330/220/392/171/26
AstheniaGeneral disorders0/310/303/331/220/390/170/26
Abdominal painGastrointestinal disorders1/310/300/331/223/390/170/26
DiarrhoeaGastrointestinal disorders1/310/300/330/220/390/172/26
DehydrationMetabolism and nutrition disorders0/310/301/330/220/390/172/26
AnaemiaBlood and lymphatic system disorders1/310/300/330/221/391/172/26
Acute kidney injuryRenal and urinary disorders0/310/300/330/223/390/172/26
Mental status changesPsychiatric disorders0/310/300/330/221/390/172/26
PneumoniaInfections and infestations1/312/301/330/222/390/170/26
Most frequent other events
Showing 10 of 178
Most frequent other events
EventMLN0128 QDMLN0128 QWMLN0128 QDx3d QWMLN0128 QDx5d QWMLN0128 5 mg QDMLN0128 30 mg QWMLN0128 40 mg QW
FatigueGeneral disorders10/319/3015/337/2225/3911/1724/26
HyperglycaemiaMetabolism and nutrition disorders26/3118/3022/3312/2218/3912/1720/26
NauseaGastrointestinal disorders16/3122/3024/3313/2221/3912/1720/26
VomitingGastrointestinal disorders12/3120/3020/3312/2212/399/1720/26
StomatitisGastrointestinal disorders11/3110/3022/3313/2219/399/1711/26
Decreased appetiteMetabolism and nutrition disorders13/3112/3020/339/2220/397/1714/26
DiarrhoeaGastrointestinal disorders14/3110/3017/339/2220/399/1711/26
AstheniaGeneral disorders7/3115/3013/3310/227/392/175/26
ConstipationGastrointestinal disorders1/316/306/333/2210/398/1710/26
Rash maculo-papularSkin and subcutaneous tissue disorders3/310/301/332/2217/394/173/26

Baseline characteristics

All Participants as Treated (ASaT) population included all participants who received at least 1 dose of MLN0128.

Age, Continuous
Age, Continuous(years)MLN0128 QDMLN0128 QWMLN0128 QDx3d QWMLN0128 QDx5d QWMLN0128 5 mg QDMLN0128 30 mg QWMLN0128 40 mg QWTotal
Mean59.7 (24 to 75)53.8 (34 to 89)56.1 (36 to 87)58.1 (32 to 75)58.8 (30 to 81)59.7 (32 to 76)63.2 (44 to 80)58.31 (24 to 89)
Sex: Female, Male
Sex: Female, Male(Participants)MLN0128 QDMLN0128 QWMLN0128 QDx3d QWMLN0128 QDx5d QWMLN0128 5 mg QDMLN0128 30 mg QWMLN0128 40 mg QWTotal
Female1618221316614105
Male151211923111293
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MLN0128 QDMLN0128 QWMLN0128 QDx3d QWMLN0128 QDx5d QWMLN0128 5 mg QDMLN0128 30 mg QWMLN0128 40 mg QWTotal
Hispanic or Latino11117981249
Not Hispanic or Latino20192613301624148
Unknown or Not Reported00001001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MLN0128 QDMLN0128 QWMLN0128 QDx3d QWMLN0128 QDx5d QWMLN0128 5 mg QDMLN0128 30 mg QWMLN0128 40 mg QWTotal
American Indian or Alaska Native00000000
Asian10001002
Native Hawaiian or Other Pacific Islander00000000
Black or African American21300006
White28293022371725188
More than one race00000011
Unknown or Not Reported00001001
Region of Enrollment
Region of Enrollment(Participants)MLN0128 QDMLN0128 QWMLN0128 QDx3d QWMLN0128 QDx5d QWMLN0128 5 mg QDMLN0128 30 mg QWMLN0128 40 mg QWTotal
United States21181912321525142
Spain1012141072156
08

Study locations

16 sites
  • Scottsdale, Arizona, United States
  • Los Angeles, California, United States
  • Miami, Florida, United States
  • Sarasota, Florida, United States
  • Indianapolis, Indiana, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • Cleveland, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Philadelphia, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Barcelona, Spain
  • Valencia, Spain
09

References and documents

Publications

  • Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, Enke A, Shou Y, Sedarati F, Faller DV, Burris HA 3rd. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer. 2020 Nov;123(11):1590-1598. doi: 10.1038/s41416-020-01041-x. Epub 2020 Sep 11. PubMed 32913286 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2010 to primary completion in Feb 2019, 109 months.

Results were first posted in Apr 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2010
First posted
Jan 29, 2010
StartActual
Jan 4, 2010
Primary completionActual
Feb 7, 2019
CompletionActual
Feb 7, 2019
Results first posted
Apr 1, 2020
Last update
Apr 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01058707
Responsible party
Sponsor
First posted
Jan 29, 2010
Start date
Jan 4, 2010
Primary completion
Feb 7, 2019
Completion
Feb 7, 2019
Results posted
Apr 1, 2020
Last update
Apr 1, 2020

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sapanisertib

Start the discussion